Current read
Editorial placement: Early human evidence
Graph-derived stage: Proof of concept
Override reason: The current graph has live regenerative-medicine and early human translation signals, but not enough mature functional outcome evidence to call this clinical traction.
Proof of concept from 0 study records, 5 active source records, 14 rapid briefs, and 0 timeline events. Evidence maturity is 0/100, human translation signal is 36/100, and frontier activity is extreme (100/100). Frontier activity means research movement, not settled human proof. Editorial placement shown publicly: Early human evidence. Graph-derived stage: Proof of concept. Override note: The current graph has live regenerative-medicine and early human translation signals, but not enough mature functional outcome evidence to call this clinical traction.
Human evidence exists, but durability, endpoint quality, or population fit still limits the claim.
Commercial bias penalty: 56/100. Confidence: 15/100. Frontier activity means research movement, not settled human proof.
Why this row matters
DNA methylation clocks, partial reprogramming, and attempts to reset age-linked cell state without losing identity. The map tracks whether this lane is moving from biological plausibility toward outcomes people can responsibly discuss.
Current human translation
Human translation is 0/100 based on human-facing studies, clinical/regulatory sources, claims, and published coverage.
Main approaches being tracked
DNA methylation clocks, partial reprogramming, retinal rejuvenation trials.
What would move this row up?
Current bottleneck
evidence maturity, human age-reversal translation, safety boundaries
Milestones that would move this row up
What could move it down
- Safety failures that limit tissue-specific reprogramming
- Clock changes fail to translate into functional outcomes
Row movement
Mini timeline
Newest graph events across studies, sources, briefs, claims, and timeline records
Open evidence gaps
These gaps are matched from the evidence-gap ledger where possible, with row-level placeholders used when the graph is not yet enriched.
Durable functional outcomes after tissue-specific reprogramming, not only clock movement.
Durable functional outcomes after tissue-specific reprogramming, not only clock movement.
Cancer, dedifferentiation, and off-target safety follow-up in humans.
Cancer, dedifferentiation, and off-target safety follow-up in humans.
Evidence that would change the map
- Raise evidence maturity from 0/100 with better controlled studies or stronger replication.
- Raise human translation from 0/100 with outcomes that matter in people, not only biomarkers or mechanisms.
- Preserve safety discipline with clearer limitations, contraindications, and overclaim boundaries as activity grows.
What not to overclaim
- Do not frame clock movement as whole-body age reversal.
- Do not generalize one tissue or early safety trial to systemic rejuvenation.
Research map
Related studies
Study records matched through topic tags, intervention IDs, source IDs, related content, or row-specific tags.
No structured study records are attached to this row yet.
Useful source library entries
Related briefs
Australia's First Child on EB Gene Therapy Is Walking More After Wound Healing
Jacob Burmeister's EB gene-therapy access story is emotionally strong, but it is based on a local/paywalled patient report plus non-Australian regulatory context. Keep draft until Australian access details are directly confirmed.
Why now
The human story is a strong example of rare-disease access friction, but the Australian-specific claim needs better direct sourcing.
- Overclaim risk
- high
- Primary source
- Trade news
- Published
- Jul 9, 2026
First Child Received Experimental Gene Therapy for Cockayne Syndrome
Riaan Singh Digeorge became the first reported patient to receive experimental AAV9 gene therapy for Cockayne syndrome after a parent-led development effort.
Why now
The first-patient milestone turns an ultra-rare parent-led research program into a live human gene-therapy story.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
FDA Expanded CRISPR Therapy to Children as Young as 2
Casgevy's label expansion moves CRISPR-based treatment access earlier for some children with sickle cell disease or transfusion-dependent beta thalassemia, but the treatment remains intensive and transplant-like.
Why now
The age expansion moves CRISPR medicine from teens and adults into much younger children for two severe inherited blood disorders.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
Rett Gene Therapy Shows Developmental Milestone Gains in Early Trial
Neurogene says 10 Rett syndrome participants treated with NGN-401 gained developmental milestones through up to 30 months of follow-up.
Why now
Rett stories are emotionally powerful because development can regress after early childhood milestones.
- Overclaim risk
- high
- Primary source
- Trade news
- Published
- Jun 30, 2026
Parent-Led FOXG1 Gene Therapy Moves Toward Patient Trial
CIRM awarded $4.9 million to advance FRF-001, an AAV9 gene therapy for FOXG1 syndrome, through a Phase 1/2 clinical trial.
Why now
Parent-led foundations are increasingly becoming drug-development engines for devastating rare pediatric disorders.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jun 30, 2026
Epigenetic Gene Therapy Shows Early Muscle Gains in FSHD Patients
Epicrispr says its one-time EPI-321 therapy increased lean muscle volume in three patients with facioscapulohumeral muscular dystrophy.
Why now
Epigenetic editing is a new category readers will share, especially with early muscle-volume signals.
- Overclaim risk
- high
- Primary source
- Trade news
- Published
- Jun 30, 2026